David A. Priestman - Concepedia

Author

David A. Priestman

Also Known As

D A Priestman, D. A. Priestman, D. Priestman, D.A Priestman, DAVID A. PRIESTMAN, David A Priestman, David A. Priestman, David PRIESTMAN, David Priestman, Priestman, David

Publications

3.3K

Citations

H-Index

105

Concepts

All Affiliations

University of Oxford Queen Mary University of London Harvard University John Radcliffe Hospital Royal Hospital for Children

About

David A. Priestman is an author at University of Oxford specializing in medicine, biochemistry, and health sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	20	1.5K
2	Health Sciences	7	7	395
3	Natural Sciences	3	3	245
4	Social Sciences	2	2	69
5	Engineering	1	1	39

David A. Priestman

Publications

2.7K

Citations

H-Index

Page 1

	Year	Citations
Infantile-onset symptomatic epilepsy syndrome caused by a homozygous loss-of-function mutation of GM3 synthase Michael A. Simpson, Christos Proukakis, David A. Priestman, Nature Genetics Mendelian DisorderGenetic DisorderGeneticsHomozygous Loss-of-function MutationNeuroscience	2004	381
Analysis of fluorescently labeled glycosphingolipid-derived oligosaccharides following ceramide glycanase digestion and anthranilic acid labeling David C. A. Neville, Virginie Coquard, David A. Priestman, Analytical Biochemistry Bioorganic ChemistryBiochemistryAnthranilic Acid LabelingNatural SciencesGlycosphingolipid-derived Oligosaccharides	2004	175
Heat shock protein–based therapy as a potential candidate for treating the sphingolipidoses Thomas Kirkegaard, James Gray, David A. Priestman, Science Translational Medicine Potential CandidateProteinlipid InteractionThermal TherapyDermatologyHsp70 Treatment	2016	172
Fetal gene therapy for neurodegenerative disease of infants Giulia Massaro, Citra Nurfarah Zaini Mattar, Andrew M.S. Wong, Nature Medicine Gene TherapiesNeurodegenerative DiseasesMedicineFetal MedicineNeurology	2018	162
Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson’s disease Mylene Huebecker, Elizabeth B. Moloney, Aarnoud C. van der Spoel, Molecular Neurodegeneration	2019	162
Implications for invariant natural killer T cell ligands due to the restricted presence of isoglobotrihexosylceramide in mammals Anneliese O. Speak, Mariolina Salio, David C. A. Neville, Proceedings of the National Academy of Sciences	2007	146
Mutations in B4GALNT1 (GM2 synthase) underlie a new disorder of ganglioside biosynthesis Gaurav V. Harlalka, Anna Lehman, Barry A. Chioza, Brain GeneticsGlycobiologyMolecular BiologyMolecular GeneticsComplex Ganglioside Biosynthesis	2013	139
A novel approach to analyze lysosomal dysfunctions through subcellular proteomics and lipidomics: the case of NPC1 deficiency Arun Kumar Tharkeshwar, Jesse Trekker, Wendy Vermeire, Scientific Reports	2017	121
Amyotrophic lateral sclerosis and denervation alter sphingolipids and up-regulate glucosylceramide synthase Alexandre Henriques, Vincent Croixmarie, David A. Priestman, Human Molecular Genetics Denervation Alter SphingolipidsNeuroinflammationSkeletal MuscleExperimental NeuropathologyNeurology	2015	92
Glycosphingolipid levels and glucocerebrosidase activity are altered in normal aging of the mouse brain Penelope J. Hallett, Mylene Huebecker, Oeystein Roed Brekk, Neurobiology of Aging	2018	81

Page 1